SOURCE: Diaceutics


November 15, 2011 13:37 ET

Tiffany Olson, Formerly of Eli Lilly and Company, Appointed Chairman of Board of Advisors of Diaceutics

WASHINGTON, DC--(Marketwire - Nov 15, 2011) - Diaceutics, a highly focused, international business consulting and software application firm that advises pharmaceutical companies on the development of personalized medicine, has appointed Tiffany Olson as Chairman of its Board of Advisors. She was most recently the Vice President and Global Head of Diagnostics for Eli Lilly and Company, and formerly the President and CEO of Roche Diagnostics.

"Diaceutics is privileged to have an individual as respected and experienced as Tiffany to lead our board," said Peter Keeling, chief executive officer of Diaceutics. "Her broad understanding of diagnostic development and the therapeutic life cycle planning process brings invaluable perspective and insight to Diaceutics."

Ms. Olson holds a Bachelor of Science in business from the University of Minnesota and an MBA from the University of St. Thomas, Minnesota. She has broad experience in diagnostic development and commercialization, as well as significant understanding of laboratory development, and market, customer and patient needs.

In her most recent position at Eli Lilly and Company she was responsible for developing and implementing its diagnostic strategy and providing innovative solutions to enable the integration of diagnostics into pharmaceutical development for personalized medicine.

"Personalized medicine is the future of healthcare and it's poised to transform the way drugs are developed and prescribed," said Ms. Olson. "Diaceutics is the industry leader in personalized medicine consulting and software applications. Their expertise is helping to lead this change."

Ms. Olson was the first woman to receive the prestigious LifeScience Alley, Luminary Award for her "rich career in medical diagnostics; exceptional reputation as a leader in this field and her vision to drive both innovation and value for personalized medicine."

Ms. Olson replaces Dr. Brent Vose, formerly the vice president and head of oncology and infection therapy with responsibility for personalized medicine at AstraZeneca.

"We appreciate the invaluable advice and guidance provided by Dr. Vose over the past year and look forward to future collaboration with him," said Keeling.

Diaceutics ( is a highly focused business consulting and software application firm improving overall return on investment in personalized medicine by providing pharmaceutical development teams the knowledge, evidence, tools and operational structure to effectively commercialize and successfully launch targeted therapies.

Contact Information

  • Contact:
    Mollie Roth, Esq.
    Chief Operating Officer
    Email Contact